These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31042137)

  • 1. Long-term disease control in a metastatic squamous cell carcinoma of the oral cavity treated with maintenance metronomic capecitabine.
    Muratori L; La Salvia A; Gorzegno G; Sperone P; Scagliotti GV
    J Oncol Pharm Pract; 2020 Jan; 26(1):240-243. PubMed ID: 31042137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
    Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
    Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
    Weiss JM; Bagley S; Hwang WT; Bauml J; Olson JG; Cohen RB; Hayes DN; Langer C
    Cancer; 2016 Aug; 122(15):2350-5. PubMed ID: 27197056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
    Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
    Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
    Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
    Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
    Szturz P; Seiwert TY; Vermorken JB
    J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
    [No Abstract]   [Full Text] [Related]  

  • 10. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
    Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
    Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma.
    Yanamoto S; Umeda M; Kioi M; Kirita T; Yamashita T; Hiratsuka H; Yokoo S; Tanzawa H; Uzawa N; Shibahara T; Ota Y; Kurita H; Okura M; Hamakawa H; Kusukawa J; Tohnai I
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):549-554. PubMed ID: 29383483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
    Tiwari S; Goel V; John MC; Patnaik N; Doval DC
    Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
    Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
    Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy after progression on nivolumab is essential for responders with genetic alterations of driver gene: Review of two recurrent/metastatic oral squamous cell carcinoma patients.
    Ogi K; Kobayashi J; Nakagaki T; Okamoto J; Koike K; Hirokawa N; Someya M; Sakamoto H; Takada K; Tokino T; Sasaki Y; Hiratsuka H; Miyazaki A
    Oral Oncol; 2020 Mar; 102():104509. PubMed ID: 31839407
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer.
    Addeo R; Montella L; Mastella A; Vincenzi B; Mazzone S; Ricciardiello F; Del Prete S
    Oncology; 2018; 95(6):353-359. PubMed ID: 30184543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
    Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
    Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Calderwood SK; Okamoto K; Kozaki KI
    Oral Oncol; 2018 Nov; 86():251-257. PubMed ID: 30409309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
    JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
    Patil VM; Noronha V; Joshi A; Dhumal S; Mahimkar M; Bhattacharjee A; Gota V; Pandey M; Menon N; Mahajan A; Sable N; Kumar S; Nawale K; Mukadam S; Solanki B; Das S; Simha V; Abraham G; Chandrasekharan A; Talreja V; DSouza H; Srinivas S; Kashyap L; Banavali S; Prabhash K
    J Clin Oncol; 2019 Nov; 37(32):3032-3041. PubMed ID: 31539316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
    Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
    Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.